Cerus Corporation (NASDAQ:CERS) Announces Amended Growth Capital Deal

Cerus Corporation (NASDAQ:CERS) reported that it has finalized a $40 million amended growth capital agreement with Oxford Finance LLC, a firm that offers senior debt to healthcare services and life sciences firms globally. Under the amended facility, the company obtained an immediate loan of $30 million at closing on July 2017 and has the alternative […]

Cerus Corporation (NASDAQ:CERS): FDA Approved Expanded Access IDE for INTERCEPT Blood System

Boston, MA 10/07/2014 (wallstreetpr) – Cerus Corporation (NASDAQ:CERS)’s clinical protocol for the INTERCEPT Blood System for platelets got accepted by the U.S. FDA. The protocol submission was to make the INTERCEPT for available under an Expanded Access IDE (Investigational Device Exemption) to regions with outbreaks of dengue and Chikungunya virus. This approval will allow use of […]

Cerus Corporation (NASDAQ:CERS) Requests FDA To Allow Intercept Blood System Immediately In Select U.S. Regions

Boston, MA 09/10/2014 (wallstreetpr) – Cerus Corporation (NASDAQ:CERS) today reported that it has tendered a clinical protocol to the U.S. Food and Drug Administration to gain its approval on providing the company’s Intercept Blood System for platelets to blood banks in the U.S. hospitals in areas witnessing outburst of dengue and Chikungunya. Awaited Approval Cerus Corporation […]

Cerus Corporation (NASDAQ:CERS) stock record 52 week high pricing

Boston, MA 10/01/2013 (wallstreetpr) – On September 20, Cerus Corporation (NASDAQ:CERS) stock charted close to 6% increase in value from its previous day’s close. At current valuations, the stock is trading at 4.5% above its prior 52 week high valuations and is up 150% from its 52 week lowest pricing point. Company attracted undue attention […]